Colon biopsy discovery cohorts (in silico)—IBD predictive gene signatures and patient cohorts used in the immune contribution analysis and cell-type meta-analysis, respectively
| Signature/cohort* | Genes in signature | IBD type | Response† | GEO dataset | Associated publication | |
| R | NR | |||||
| UC-A | 20 | UC | 8 | 16 | GSE14580 | 10 |
| UC-B UC-B-knn IRRAT | 20 19 29 | UC | 12 | 10 | GSE12251 | 10 14 15 |
| UC-AB‡ | 53 | UC | 8 12 | 16 10 | GSE14580 GSE12251 | 10 |
| CDc | 20 | CD | 12 | 7 | GSE16879 | 11 |
*Details of the previously reported gene signatures, grouped according to the cohort in which they were identified to be predictive of infliximab response. Underlined names being used as cohort names.
†R/NR number in each cohort
‡Signature defined from overlap between cohort UC-A and UC-B.
CDc, Crohn’s disease cohort; NR, non-responder; R, responder.